Giant Biogene Holding Co Ltd
Giant Biogene Holding Co Ltd is a personal care products company that develops, produces, and sells beauty and personal care products, primarily in the Chinese market.
Business. Giant Biogene Holding Co Ltd (2367.HK) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm generates revenue through the sale of personal care items and is headquartered in Hong Kong, where it is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Analyst recommendations
22 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Giant Biogene Holding Co Ltd (2367.HK) is a personal products company operating within the Consumer Non-Cyclicals sector. The firm generates revenue through the sale of personal care items and is headquartered in Hong Kong, where it is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Giant Biogene has a market capitalization of 28.98 billion CNY, with a current market price of 27.3 CNY per share. The company has 1.06 billion shares outstanding, with no dilution from potential share issuance as of the latest data. Analysts have assigned a mean price target of 46.99 CNY, with a median of 44.00 CNY, indicating a potential upside of 72.1% from the current price.
The company's profitability and return metrics are not available in the current dataset, which limits the ability to compare its performance against industry benchmarks. However, the absence of detailed financial metrics does not necessarily indicate poor performance, but rather a lack of disclosed data for analysis.
Giant Biogene's geographic and segment exposure is not explicitly detailed in the available data, but as a personal care products company, it is likely concentrated in the Chinese market. The company's revenue concentration and segment breakdown are not disclosed, which limits the ability to assess diversification risk.
The company's growth trajectory is not quantified in the current dataset, but analyst price targets suggest a positive outlook. The mean recommendation of 1.77 (on a scale of 1 to 5) indicates a generally favorable sentiment among analysts, with 8 strong-buy and 11 buy ratings.
The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The dilution risk is currently low, with no evidence of potential share issuance or capital-raising activities.
No recent events, such as filings or transcripts, are available in the current dataset to provide insight into the company's recent developments or strategic direction.
- Analysts have a generally positive outlook on Giant Biogene, with a mean price target of 46.99 CNY and a median of 44.00 CNY.
- The company has a market capitalization of 28.98 billion CNY and no dilution from potential share issuance.
- The company's profitability and return metrics are not available, limiting the ability to compare its performance against industry benchmarks.
- The company's geographic and segment exposure is not explicitly detailed, but it is likely concentrated in the Chinese market.
- The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥5.52B, −0,4% YoY; Operating income −4,9% YoY.
- ▍Revenue ¥5.52B, −0,4% YoY
- ▍Operating income −4,9% YoY
- ▍Net income −7,2% YoY
- ▍Free cash flow −69,8% YoY
- ▍Net margin 34.7%
Revenue ¥5.54B, +57,2% YoY; Operating income +41,1% YoY.
- ▍Revenue ¥5.54B, +57,2% YoY
- ▍Operating income +41,1% YoY
- ▍Net income +42,1% YoY
- ▍Free cash flow −23,8% YoY
- ▍Net margin 37.2%
Revenue ¥3.52B, +49,0% YoY; Operating income +48,1% YoY.
- ▍Revenue ¥3.52B, +49,0% YoY
- ▍Operating income +48,1% YoY
- ▍Net income +44,9% YoY
- ▍Free cash flow +43,2% YoY
- ▍Net margin 41.2%
Revenue ¥2.36B, +52,3% YoY; Operating income +21,1% YoY.
- ▍Revenue ¥2.36B, +52,3% YoY
- ▍Operating income +21,1% YoY
- ▍Net income +21,0% YoY
- ▍Free cash flow +18,4% YoY
- ▍Net margin 42.4%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,86 |
| Revenue | —no estimate | —no estimate | 6,1B CNY |
| Operating income | —no estimate | —no estimate | 2,2B CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Giant Biogene Holding Co Ltd Market data — financials · 2026-05-26
- Giant Biogene Holding Co Ltd Market data — analyst estimates · 2026-05-26
- Giant Biogene Holding Co Ltd Market data — ESG · 2026-05-26
Ownership & reference
Leadership
- Yajuan YanSenior Vice President
- Zhiguang DuanSenior Vice President